AACR Basic Science of Sarcomas

At this CTOS companion meeting, we presented our work on the dynamic (cell cycle dependent) expression of the Pax3:Foxo1 oncogene in rhabdomyosarcoma, and how re-purposing an adult breast cancer drug might be used to silence Pax3:Foxo1 in order to reverse its effects on chemotherapy resistance (and relapse).      

Share this post
Facebook
Google+
Twitter
LinkedIn
Close Menu